A clinical report also indicates that plasma levels of 8-iso-PGF2α are reduced after 26 weeks of GLP1-RA administration in patients with T2DM, suggesting a reduction in oxidative stress through reduced ROS production and increased antioxidant capacity, partly independent of the glucose-lowering effect [22]. This evidence concerns the gene GCG and type 2 diabetes mellitus.